- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Johnson & Johnson Announces Partnership with CSIR-IMTECH to Develop Innovative New Tuberculosis Treatments
Memorandum of Understanding brings together best scientists from India and Johnson & Johnson to increase and accelerate pace of innovation needed to make TB history
Janssen Enters Collaboration with Bavarian Nordic to Develop Vaccines Against Hepatitis B Virus and HIV-1
Collaboration to combine Janssen’s vaccine technologies with MVA-BN® technology from Bavarian Nordic to advance potential new vaccine regimens
Janssen Receives Positive CHMP Opinion for SYMTUZA™ The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV
- Proven efficacy and durability of darunavir combined with the improved renal laboratory and bone mineral density profile of emtricitabine/tenofovir alafenamide as compared to emtricitabine/tenofovir disoproxil fumarate into one single tablet
Johnson & Johnson at IAS 2017: Latest Innovations from its Janssen Pharmaceutical Companies Include First In-Human Data for Investigational Preventive HIV-1 Vaccine and Phase 3 Pivotal Trial Results for Darunavir-Based, Single-Tablet Regimen
First in-human, Phase 1/2a data from APPROACH preventive HIV-1 vaccine clinical trial to be featured in oral presentation and included in official IAS press program. Interim results from the Phase 3 pivotal EMERALD trial investigating darunavir-based single-tablet regimen selected for oral presentation; data submitted to regulatory authorities for EMA approval, September 2017.